Search

Your search keyword '"Wei, Kuo Liang"' showing total 139 results
Start Over Author "Wei, Kuo Liang"
139 results on '"Wei, Kuo Liang"'

3. Immunological hide-and-seek: epigenetically reprogrammed cancer cells and the dynamics of CD8+ T cells.

Author

Low, Jie-Ting, Chan, Michael W.Y., Shen, Cheng-Huang, and Wei, Kuo-Liang

Abstract

Cancer remains a global health burden, shaped by both genetic mutations and epigenetic dysregulation. Epigenetic alteration plays a pivotal role in tumorigenesis, immune response modulation, and the emergence of treatment resistance. This review emphasizes the intricate interplay between epigenetically reprogrammed cancer cells and the tumor microenvironment (TME), a relationship central to the immunoediting concept, which encompasses elimination, equilibrium, and escape phases. This review highlights the significance of CD8+ T cells as potent anticancer agents and discusses the mechanisms by which tumor cells evade immune surveillance and evolve resistance to immunotherapy. Such evasion entails the regulation of inhibitory molecules, antigen presentation machinery, and cytokine milieu. Furthermore, this review explores the complex dynamics culminating in CD8+ T cell dysfunction within the TME. In summary, this work offers insights into the indispensable role of epigenetic mechanisms in bolstering cancer cell survival amidst immunological challenges within the TME. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Factors Associated with Large Renal Function Decline in Patients with Chronic Hepatitis C Successfully Treated with Direct-Acting Antiviral Therapy

Author

Chen, Chun-Hsien, primary, Shen, Chien-Heng, additional, Wei, Kuo-Liang, additional, Xu, Huang-Wei, additional, Chen, Wei-Ming, additional, Chang, Kao-Chi, additional, Huang, Yu-Ting, additional, Hsieh, Yung-Yu, additional, Lu, Sheng-Nan, additional, Hung, Chao-Hung, additional, and Chang, Te-Sheng, additional

Published
2023
Full Text
View/download PDF

8. Direct-Acting Antivirals Reduce the De Novo Development of Esophageal Varices in Patients with Hepatitis C Virus Related Liver Cirrhosis

Author

Hsieh, Yung-Yu, primary, Chen, Wei-Ming, additional, Chang, Kao-Chi, additional, Chang, Te-Sheng, additional, Hung, Chao-Hung, additional, Yang, Yao-Hsu, additional, Tung, Shui-Yi, additional, Wei, Kuo-Liang, additional, Shen, Chen-Heng, additional, Wu, Cheng-Shyong, additional, Ding, Yuan-Jie, additional, Hu, Jing-Hong, additional, Huang, Yu-Ting, additional, Lin, Meng-Hung, additional, Lu, Chung-Kuang, additional, Lin, Yi-Hsiung, additional, and Lin, Ming-Shyan, additional

Published
2023
Full Text
View/download PDF

9. Changes in renal function in patients with chronic hepatitis C treated with sofosbuvir‐velpatasvir

Author

Su, Pei‐Kai, primary, Chang, Te‐Sheng, additional, Tung, Shui‐Yi, additional, Wei, Kuo‐Liang, additional, Shen, Chien‐Heng, additional, Hsieh, Yung‐Yu, additional, Chen, Wei‐Ming, additional, Chen, Yi‐Hsing, additional, Chen, Chun‐Hsien, additional, Yen, Chih‐Wei, additional, Xu, Huang‐Wei, additional, Tung, Wei‐Ling, additional, and Chang, Kao‐Chi, additional

Published
2022
Full Text
View/download PDF

10. Changes in renal function in patients with chronic hepatitis C treated with sofosbuvir‐velpatasvir

Author

Su, Pei‐Kai, Chang, Te‐Sheng, Tung, Shui‐Yi, Wei, Kuo‐Liang, Shen, Chien‐Heng, Hsieh, Yung‐Yu, Chen, Wei‐Ming, Chen, Yi‐Hsing, Chen, Chun‐Hsien, Yen, Chih‐Wei, Xu, Huang‐Wei, Tung, Wei‐Ling, and Chang, Kao‐Chi

Abstract

Direct‐acting antivirals (DAAs) have become an effective first‐line treatment for chronic hepatitis C (CHC), and the fixed‐dose combination of sofosbuvir (SOF) and velpatasvir (VEL) is one of the most important pangenotypic DAA regimen according to present treatment guideline. The association between SOF‐based regimens and renal toxicity remains controversial. A total of 953 patients including 130 with estimated glomerular filtration rate (eGFR) ≤ 60 mL/min/1.73m2and 823 with eGFR > 60 mL/min/1.73m2receiving SOF/VEL therapy for 12 weeks were enrolled in this study. The eGFR was assessed at baseline, end of treatment (EOT), and 12 weeks after completion of the therapy (end of follow‐up, EOF). The eGFR in patients with eGFR ≤ 60 mL/min/1.73m2increased from baseline (47.89 ± 10.25 mL/min/1.73m2) to EOT (51.65 ± 15.92; P< .001) and EOF (51.51 ± 14.46 mL/min/1.73m2; P< .05). The eGFR in patients with eGFR > 60 mL/min/1.73m2at baseline (91.52 ± 22.06 mL/min/1.73m2) was lower at EOT (90.37 ± 22.3; P< .05), with no difference between EOT and EOF (P= .06). Multivariable analysis showed that a higher serum albumin level was associated with a lower risk of eGFR decrease at EOT, and the patients with baseline eGFR > 60 mL/min/1.73m2were associated with a higher risk of eGFR decrease at EOF. The rates of sustained virologic response 12 weeks after treatment cessation (SVR12) were 99.2% in per‐protocol analysis, and the most common adverse events were fatigue (4.7%), abdominal discomfort (4.5%), and skin itching (3.7%). In conclusion, renal function improved after the SOF/VEL treatment in patients with CHC and chronic kidney disease. Thus, SOF/VEL was safe, effective, and tolerable in these patients.

Published
2023
Full Text
View/download PDF

14. Pangenotypic direct‐acting antiviral agents for mixed genotype hepatitis C infection: A real‐world effectiveness analysis

Author

Ding, Yuan‐Jie, primary, Lu, Chung‐Kuang, additional, Chen, Wei‐Ming, additional, Tung, Shui‐Yi, additional, Wei, Kuo‐Liang, additional, Shen, Chen‐Heng, additional, Hsieh, Yung‐Yu, additional, Yen, Chih‐Wei, additional, Chang, Kao‐Chi, additional, Chiu, Wen‐Nan, additional, Hung, Chao‐Hung, additional, Lu, Sheng‐Nan, additional, and Chang, Te‐Sheng, additional

Published
2021
Full Text
View/download PDF

16. Epigenetic Silencing of STAT3-Targeted miR-193a, by Constitutive Activation of JAK/STAT Signaling, Leads to Tumor Progression Through Overexpression of YWHAZ in Gastric Cancer

Author

Wei, Kuo-Liang, primary, Chou, Jian-Liang, additional, Chen, Yin-Chen, additional, Low, Jie-Ting, additional, Lin, Guan-Ling, additional, Liu, Jing-Lan, additional, Chang, Te-Sheng, additional, Chen, Wei-Ming, additional, Hsieh, Yung-Yu, additional, Yan, Pearlly S., additional, Chuang, Yu-Ming, additional, Lin, Jora M. J., additional, Wu, Shu-Fen, additional, Chiang, Ming-Ko, additional, Li, Chin, additional, Wu, Cheng-Shyong, additional, and Chan, Michael W. Y., additional

Published
2021
Full Text
View/download PDF

17. Real-World Efficacy and Safety of Pangenotypic Direct-Acting Antivirals Against Hepatitis C Virus Infection in Taiwan

Author

Chang, Kao-Chi, primary, Tung, Shui-Yi, additional, Wei, Kuo-Liang, additional, Shen, Chen-Heng, additional, Hsieh, Yung-Yu, additional, Chen, Wei-Ming, additional, Chen, Yi-Hsing, additional, Chen, Chun-Hsien, additional, Yen, Chi-Wei, additional, Xu, Huang-Wei, additional, Tung, Wei-Lin, additional, Hung, Chao-Hung, additional, Lu, Sheng-Nan, additional, and Chang, Te-Sheng, additional

Published
2021
Full Text
View/download PDF

18. High viral load predicts virologic failure in chronic genotype 2 hepatitis C virus-infected patients receiving glecaprevir/pibrentasvir therapy

Author

Chen, Wei-Ming, primary, Wei, Kuo-Liang, additional, Tung, Shui-Yi, additional, Shen, Chien-Heng, additional, Chang, Te-Sheng, additional, Yen, Chih-Wei, additional, Hsieh, Yung-Yu, additional, Chiu, Wen Nan, additional, Hu, Jin Hung, additional, Lu, Sheng-Nan, additional, and Hung, Chao-Hung, additional

Published
2020
Full Text
View/download PDF

21. Real‐world effectiveness of glecaprevir/pibrentasvir and ledipasvir/sofosbuvir for mixed genotype hepatitis C infection: A multicenter pooled analysis in Taiwan

Author

Chiu, Wen‐Nan, primary, Hung, Chao‐Hung, additional, Lu, Sheng‐Nan, additional, Chen, Mei‐Yen, additional, Tung, Shui‐Yi, additional, Wei, Kuo‐Liang, additional, Lu, Chung‐Kuang, additional, Chen, Chien‐Hung, additional, Hu, Tsung‐Hui, additional, Hu, Jin‐Hung, additional, Chen, Wei‐Ming, additional, and Chang, Te‐Sheng, additional

Published
2020
Full Text
View/download PDF

22. Clinical utility of hepatitis C virus core antigen assay in the monitoring of direct-acting antivirals for chronic hepatitis C

Author

Lin, Sheng Feng, primary, Tung, Shui-Yi, additional, Wei, Kuo-Liang, additional, Chen, Chien-Hung, additional, Hu, Tsung-Hui, additional, Shen, Chien Heng, additional, Chang, Te-Sheng, additional, Chen, Wei-Ming, additional, Yen, Chih-Wei, additional, Wang, Jing-Houng, additional, Hung, Chao-Hung, additional, and Lu, Sheng-Nan, additional

Published
2020
Full Text
View/download PDF

23. Incidence, risk factors and impact on virological response of anemia in chronic genotype 2 hepatitis C receiving sofosbuvir plus ribavirin

Author

Chen, Chi-Ching, primary, Tung, Shui-Yi, additional, Wei, Kuo-Liang, additional, Shen, Chien-Heng, additional, Chang, Te-Sheng, additional, Chen, Wei-Ming, additional, Xu, Huang-Wei, additional, Yen, Chih-Wei, additional, Chen, Yi-Hsing, additional, Lu, Sheng-Nan, additional, and Hung, Chao-Hung, additional

Published
2020
Full Text
View/download PDF

32. Esophageal perforation caused by a central venous catheter: A case report and literature review

Author

Chen, Wei‐Ming, Chiang, Ming‐Shih, Wang, Po‐Chang, Wei, Kuo‐Liang, Tung, Shui‐Yi, Chang, Te‐Sheng, and Hung, Chao‐Hung

Abstract

Malposition of the central venous catheter is rare but may cause morbidity and mortality. Here, we presented a male patient who suffered from a misplaced central venous catheter into the esophagus and caused perforation. We removed the misplaced central venous catheter directly after evaluated by computed tomography. We provided an available method to evaluate and solve this problem after literature view. In catheter‐related esophageal perforation patient, conservative treatment is an optional therapy after removed the misplaced catheter without fluoroscopy guided according to clinical presentation.

Published
2020
Full Text
View/download PDF

33. Prevalence and predictive value of high‐positive rheumatoid factor and anti‐citrullinated protein antibody levels in nonarthritic patients with chronic hepatitis C infection.

Author

Lin, Ko‐Ming, Chen, Wei‐Ming, Tung, Shui‐Yi, Wei, Kuo‐Liang, Shen, Chein‐Heng, Chang, Te‐Sheng, and Chang, Pey‐Jium

Subjects
CHRONIC hepatitis C, RHEUMATOID factor, HEPATITIS B, HEPATITIS C virus, FATTY liver, INFECTION
Abstract

Aim: In order to increase diagnostic sensitivity for early disease in rheumatoid arthritis (RA), new classification criteria were approved in 2010 by the American College of Rheumatology and the European League Against Rheumatism. One of the criteria, a high‐positive rheumatoid factor (RF) or anti‐citrullinated protein antibody (ACPA) level, was given a high score of 3. However, the increased prevalence of RF in patients with chronic hepatitis C virus (HCV) infection markedly diminishes the diagnostic specificity of serum RF for RA in these patients. There are no published data on the prevalence and predictive value of high‐positive RF and ACPA; thus, we investigated high‐positive RF and ACPA levels in nonarthritic patients with chronic HCV infection. Method: Anti‐citrullinated protein antibody and total RF were determined in serum from nonarthritic patients with chronic HCV infection (all had HCV RNA viremia). Result: In 271 HCV‐infected patients, positive RF, positive ACPA, high‐positive RF, and high‐positive ACPA were detectable in 47.2%, 1.1%, 8.9% and 1.1%, respectively. In these patients, fatty liver was an independent factor for high‐positive RF. Conclusion: In contrast to RF, ACPA is not increased in HCV infection. High‐positive RF is not unusually present in nonarthritic patients with chronic HCV infection. ACPA may have improved value for the diagnosis of RA in this patient population. In patients with HCV infection, fatty liver may be a risk factor for high‐positive RF. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

35. Corrigendum: Alpha-Fetoprotein Measurement Benefits Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis

Author

Chang, Te-Sheng, primary, Wu, Yu-Chih, additional, Tung, Shui-Yi, additional, Wei, Kuo-Liang, additional, Hsieh, Yung-Yu, additional, Huang, Hao-Chun, additional, Chen, Wei-Ming, additional, Shen, Chien-Heng, additional, Lu, Chang-Hsien, additional, Wu, Cheng-Shyong, additional, Tsai, Ying-Huang, additional, and Huang, Yen-Hua, additional

Published
2016
Full Text
View/download PDF

36. MicroRNA-122 as a predictor of HBsAg seroclearance in hepatitis B and C dual infected patients treated with interferon and ribavirin

Author

Yen, Yi-Hao, primary, Huang, Chao-Min, additional, Wei, Kuo-Liang, additional, Wang, Jing-Houng, additional, Lu, Sheng-Nan, additional, Lee, Chuan-Mo, additional, Hung, Chao-Hung, additional, Chen, Chien-Hung, additional, Tseng, Po-Lin, additional, Chang, Kuo-Chin, additional, Tsai, Ming-Chao, additional, Lin, Ming-Tsung, additional, Wu, Cheng-Kun, additional, Yang, Cheng-Hong, additional, Moi, Sin-Hua, additional, Cho, Chung-Lung, additional, and Hu, Tsung-Hui, additional

Published
2016
Full Text
View/download PDF

37. Aberrant JAK/STAT Signaling Suppresses TFF1 and TFF2 through Epigenetic Silencing of GATA6 in Gastric Cancer

Author

Wu, Cheng-Shyong, primary, Wei, Kuo-Liang, additional, Chou, Jian-Liang, additional, Lu, Chung-Kuang, additional, Hsieh, Ching-Chuan, additional, Lin, Jora, additional, Deng, Yi-Fang, additional, Hsu, Wan-Ting, additional, Wang, Hui-Min, additional, Leung, Chung-Hang, additional, Ma, Dik-Lung, additional, Li, Chin, additional, and Chan, Michael, additional

Published
2016
Full Text
View/download PDF

39. Abstract 1501: Aberrant JAK/STAT signaling orchestrates global promoter methylation and promotes TGF-β mediated EMT through epigenetic silencing of miR-193a in gastric cancer

Author

Lin, Jora M.j., primary, Chou, Jiang-Liang, additional, Frankhouser, David E., additional, Chuang, Yu-Ming, additional, Chang, Alex Liang-Yu, additional, Zeng, Li-Han, additional, Chen, Szu-Shan, additional, Lin, Ru-Inn, additional, Wu, Cheng-Shyong, additional, Wei, Kuo-Liang, additional, Ng, Enders K.W., additional, Yan, Pearlly S., additional, Cheng, Alfred S.L., additional, Li, Chin, additional, and Chan, Michael W. Y., additional

Published
2016
Full Text
View/download PDF

49. Antiviral Therapy Reduces Risk of Haemorrhagic Stroke in Patients with HCV Infection: A Nationwide Cohort Study

Author

Lin, Ming-Shyan, Chung, Chang-Min, Lin, Wey-Yil, Wei, Kuo-Liang, Wang, Jui, Lee, Ying-Ying, Hu, Jing-Hong, Tung, Tao-Hsin, and Lin, Yu-Sheng

Abstract

Background The tendency for haemorrhagic stroke in patients with chronic HCV infection has emerged recently but the finding may be confounded by comorbidities. Proving the causality between HCV infection and haemorrhagic stroke is mandatory. Our study was designed to investigate the incidence of intracranial haemorrhage in HCV-infected patients with and without treatment.Methods In the 11-year and population-based retrospective study, we acquired data from the Taiwan National Health Insurance Research Database. The patients with major comorbidities were excluded and 97,198 HCV-infected patients were included for analysis. Treated and untreated cohorts were matched with propensity score to make the confounding factors in two groups comparable. Cox proportional hazard regression analysis was performed to evaluate the hazard ratio of haemorrhagic stroke in the cohorts. We applied survival analysis to compare the cumulative incidence of outcome events between the two cohorts.Results After matching, the incidence density (ID) of haemorrhagic stroke in the untreated cohort is significantly higher than in the treated cohort (ID: 1.0 versus 0.6 events per 1,000 person-years; P=0.0014). The adjusted hazard ratio (aHR) of haemorrhagic stroke is significantly reduced in the treated group (P<0.05). Cumulative incidence of haemorrhagic stroke is significantly lower in the treated group than in the untreated group (P=0.013).Conclusions The study demonstrates that antiviral therapy significantly reduces the events of intracranial haemorrhage in HCV-infected patients and consolidates the novel concept that chronic HCV infection is a risk factor for haemorrhagic stroke.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results